Curateq Biologics

a wholly owned subsidiary of Aurobindo Pharma Ltd.) is an biopharmaceutical company headquartered in Hyderabad, India. Our vision is to improve the wellbeing of patients suffering from debilitating illnesses by providing them access to high quality and cost-effective biosimilars. CuraTeQ has a development pipeline of 14 biosimilars, of which, three products have been filed with EMA, one product has been filed with MHRA, and four more products are in global phase 3 clinical trials- ®,(Bevacizumab biosimilar), has received MHRA approval- ®,(Pegfilgrastim biosimilar), has received EC, MHRA, and Health Canada approval- ®,(Filgrastim biosimilar), has received EC and MHRA approval- ®,(Trastuzumab biosimilar), has received EC, MHRA, and CDSCO approval: Deliver exceptional value to stakeholders and better health outcomes to patients by becoming a leading global biosimilars developer by 2030. Build deep capabilities in development and manufacturing to deliver quality and cost-effective biosimilars for patients across the globe. Create a sustainable and broad portfolio of biosimilars with a focus on oncology and immunology therapies.